NEW YORK, March 13, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Cree, Inc. (NASDAQ: CREE), Veeco Instruments Inc. (NASDAQ: VECO),
Synopsys Inc. (NASDAQ: SNPS), Tessera Technologies Inc. (NASDAQ:
TSRA), and ATMI Inc. (NASDAQ: ATMI). Private wealth members receive
these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Cree, Inc. Analyst Notes
On March 5, 2014, Cree, Inc.
(Cree) announced the launch of the new CPW5 Z-Rec® high-power
silicon-carbide (SiC) Schottky diodes. It is the industry's first
commercially available family of 50-amp SiC rectifiers. It is
designed to reduce costs, improve efficiency, simplify systems and
increase reliability of SiC technology to high-power systems from
50 kW to over 1 MW. "As the sole distributor of Cree SiC-based
power products in wafer and die form, SemiDice is excited to offer
the CPW5 family of Z-Rec Schottky diodes," said Dan Cormack, CEO of SemiDice, Inc. "We are
seeing increased customer demand for 50-amp Schottky diodes, and we
know that as a global leader in the manufacture of advanced SiC
diodes, Cree will deliver the quality and performance that our
customers expect to help them minimize system cost and size." The
CPW5 family of Z-Rec Schottky diodes includes 1700-V/50-A,
1200-V/50-A, 650-V/50-A and 650-V/30-A combinations. The full
analyst notes on Cree, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03132014/CREE/report.pdf
--
Veeco Instruments Inc. Analyst
Notes
On March 10, 2014, Veeco
Instruments Inc. (Veeco) announced that IPG Photonics Corporation
(IPG), made a purchase of an additional GEN2000® Production
Molecular Beam Epitaxy (MBE) System to add to their fleet of Veeco
MBE systems. IPG will use the GEN2000 for high-volume manufacturing
of laser diodes for fiber lasers. "Veeco's GEN2000 is the perfect
complement to our existing set of Veeco MBE systems because of its
superior throughput and low production costs," said Dr.
Alex Ovtchinnikov, Senior Vice
President, Components at IPG Photonics. "Having the ability to
transfer production methods from our other Veeco MBE systems means
we can ramp laser diode production quickly and reliably to meet
increasing demand for our fiber lasers." IPG Photonics Corporation
is the world leader in high-power fiber lasers and amplifiers and
now utilizes multiple Veeco MBE systems in its laser production
operations. The full analyst notes on Veeco Instruments Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03132014/VECO/report.pdf
--
Synopsys Inc. Analyst Notes
On February 19, 2014, Synopsys
Inc. (Synopsys) and Coverity has signed a definitive agreement for
Synopsys to acquire Coverity, the leading provider of software
quality, testing, and security tools. Under the terms of the
definitive agreement, Synopsys will pay approximately $375 million, or $350
million net of cash acquired. In addition, Synopsys will
assume certain unvested stock options of Coverity employees. The
transaction will be funded by Synopsys with a combination of US
cash and debt, and is subject to Hart Scott Rodino regulatory
review and other customary closing conditions. The acquisition is
expected to close in Q2 FY 2014. Synopsys expects Coverity to
contribute approximately $20 million to $25
million to FY 2014 revenue. The full analyst notes on
Synopsys Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/SNPS/report.pdf
--
Tessera Technologies Inc. Analyst
Notes
On February 27, 2014, Tessera
Technologies Inc. (Tessera) announced that its subsidiary, Tessera,
Inc., has entered into a settlement agreement with Powertech
Technology, Inc., Powertech Technology (Suzhou) Co. Ltd., and
Macrotech Technology, Inc. (collectively PTI) in relation to their
pending cases in United States District Court for the Northern
District of California. Under the
terms of the settlement, PTI agrees to pay $196 million to Tessera, Inc. Further, if
Tessera, receives a majority of the total amount owed by PTI under
the settlement, and other conditions are met, by March 31, 2015, Tessera, Inc. and PTI will
dismiss the pending cases. The full analyst notes on Tessera
Technologies Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/TSRA/report.pdf
--
ATMI Inc. Analyst Notes
On February 20, 2014, ATMI, Inc.
(ATMI) announced that it has completed the sale of ATMI
LifeSciences to Pall Corp. The transaction includes all assets
associated with the LifeSciences business. Cash proceeds from the
transaction are approximately $185
million, subject to customary post-closing working capital
adjustments. ATMI will report an after-tax gain during Q1 2014
related to this transaction of approximately $68 million. The full analyst notes on ATMI Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03132014/ATMI/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review